Mettler Toledo (MTD)

Health Care · $34.7B market cap · SEC CIK 0001037646

Next reports on Feb 3, 2027, after the close, with analysts expecting $15.03 in earnings per share.

52-week range $1,023 to $1,807. 3% below its 52-week high and 71% above its low.

The case for MTD

• Generated $849M of free cash flow in FY2025, 21% of revenue.
• 22% of revenue drops through to net profit.
• Earns 25% a year on everything it owns (return on assets).
• Gross margin of 60% absorbs cost shocks.
• Within 3% of its 52-week high: the trend is up.

The case against

• Expensive for its growth: 37.1× earnings, where 8% a year of growth would justify about 20×.
• Owes more than it owns: shareholder equity is −$23.6M, usually the result of buybacks funded with debt. ROE and price-to-book mean little here.
• Priced at 8.3× sales with revenue growing only 6.5%.
• Long-term debt of $2.1B against $66.9M of cash.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Shareholder equity is negative, so return on equity, price-to-book and debt-to-equity are left out.
• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Mettler Toledo's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Mettler Toledo says it does

We are a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key research and development, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. Our business is geographically diversified, with net sales in 2025 derived 42% from North and South America, 29% from Europe, and 29% from Asia and other countries. Our customer base is…

Risk factors MTD lists in its 10-K

• Factors Affecting Our Future Operating Results
• We sell primarily to companies in developed countries. An economic downturn in these countries could hurt our operating results
• We are subject to risks associated with our international operations, including our significant concentration of business in China
• Our business and financial performance may be adversely affected by a cybersecurity attack
• We are vulnerable to system failures and data loss risks, which could harm our business
• Our ability to manufacture and deliver products and services may be disrupted
• Our business would suffer if we were unable to obtain supplies of material
• Our product development efforts may not produce commercially viable products in a timely manner
• We face risks related to sales through distributors and other third parties that we do not control, which could harm our business
• Departures of key employees could impair our operations
• We operate in highly competitive markets, and it may be difficult for us to preserve operating margins, gain market share, and maintain a technological advantage
• We may face risks associated with acquisitions
• Currency fluctuations affect our operating profits
• Inflation can impact our operating results and the global economy
• We may experience impairments of goodwill or other intangible assets
• Concerns regarding the Eurozone debt levels and market perception related to the instability of the euro could affect our operating profits
• Unanticipated changes in our tax rates or additional income tax liabilities could impact our profitability
• Our tax expense and tax obligations could increase as a result of changing the application of tax law
• We may be adversely affected by tariffs and other trade restrictions and by failure to comply with regulations of governmental agencies or by the adoption of new regulations
• If we cannot protect our intellectual property rights, or if we infringe or misappropriate the proprietary rights of others, our operating results could be harmed
• We may be adversely affected by environmental and climate change laws, regulations, and expectations
• Climate change, or the effects of climate change, may negatively affect us
• We may be adversely affected by regulations and market expectations related to sourcing and our supply chain, including conflict minerals
• Our ability to generate and repatriate cash depends in part on factors beyond our control
• We have debt and we may incur substantially more debt, which could affect our financial position and may otherwise restrict our activities
• The agreements governing our debt impose restrictions on our business
• The lenders under our credit agreement may be unable to meet their funding commitments, reducing the amount of our borrowing capacity
• We make forward-looking statements, and actual events or results may differ materially from these statements because assumptions we have made prove incorrect due to market conditions in our industries or other factors
• Our business involves certain operating risks, and our insurance may not be adequate to cover all insured losses or liabilities we might incur in our operations

Filings

Other Health Care companies